The epidermis is often the first point of contact between the immune system and the environment. Numerous cytokines are produced by cells located within the epidermis for the purpose of modulating the immune response.
Among the cytokines produced by keratinocytes are: ILle and/~ [261, murine IL-3 [31] , IL-6 [28] , GM-CSF [27] , , TNF~ [381 and TGF~ [14, 181 and/3 [115] . The epidermis can also produce inhibitors of cytokines, in particular IL-1. TGF/? can block some effects of IL-I [46] , and accounts, at least in part, for the inhibitory activity of keratinocyte lymphocyte inhibitory factor [37] . An epidermal inhibitor of IL-1 activity that is inducible by UVB radiation has also been described. This IL-I inhibitor has a molecular weight of 40 kDa and an isoelectric point of 8.8 [40] . Additional IL-1 inhibitors have been described in other systems. IL-1 inhibitors have been detected in the urine of patients with fever [30, 41] and monocytic leukemia [3] , and natural antagonists of the IL-1 receptor have been described [5, 21] .
We have previously found that IL-1 activity is markedly decreased in psoriatic epidermis [9] . This was due to a decrease in IL-lc~ protein and non-functionality of increased IL-1/? protein levels. However, the clear absence of IL-1 activity in many patient samples, despite the presence of detectable IL-lc~ (albeit at reduced levels), suggested that the reduced functional activity may also be influenced by the presence of an IL-1 inhibitor. We found that, indeed, psoriatic cytosolic extracts from involved skin, but not uninvolved skin, inhibited IL-1 activity. The epidermal IL-1 inhibitor detected in psoriatic epidermis was functionally and physicochemically characterized. Based upon these results the molecule was identified as being different from such epidermal IL-1 inhibitors as TGF/~ and the UVB-inducible keratinocyte IL-1 inhibitor.
Materials and methods

Materials
Polyethylene glycol (PEG, MW 8000), 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT), Tween 20 , and phenylmethylsulfonyl fluoride (PMSF) were obtained from Sigma Chemical Company, St. Louis, Mo., USA. A fast protein liquid chromatography (FPLC) apparatus, Mono P anion exchange column and Polybuffer 74 were purchased from Pharmacia, Piscataway, N. J., USA. A TSK G2000SW molecular sizing column was from Toyo Sodo, Tokyo, Japan. Human recombinant rILlfl was a gift from Dr. R. C. Newton (DuPont Glenolden Lab., Glenolden, Pa., USA). Peroxidase-conjugated goat anti-rabbit IgG was from Tago, Inc. (Burlingame, Calif., USA). The monoclonal antibody to TGF/~2 (1D11.16), which crossreacts with TGF/~I [11] , was obtained from Collagen Corp. (Palo Alto, Calif., USA).
Preparation of keratome biopsy cytosols
into flat-bottomed 96-well microtiter plates containing 10 000 HT-2 (20 gl) cells, an IL-2 addictive murine T-cell clone. After a 48 h incubation at 37~ viability of the HT-2 cells was tested by the degree of MTT reduced by live cells. The OD of reduced MTT was measured by an ELISA reader using wavelengths of 570 and 620 nm as described by Mosmann [35] . Quantifitation of the amount of IL-2 produced by LBRM.33 celis was made in relation to an IL-2 standard curve that had 250 U/ml of IL-2 activity (rat TCGF).
Comparison of the 50% of maximal response of the LBRM.33 sample was made with the standard to obtain the amount of IL-2 W/ml.
Keratome biopsies were taken from untreated psoriatic plaques or from normal skin of the hips or buttocks. Biopsies were taken using a Castro Viejo keratome set at 0.2-0.3 mm for normal skin and 0.5 mm for psoriatic skin. Keratome strips were immediately snap frozen in liquid nitrogen.
Keratome biopsies were pulverized under liquid nitrogen, then Dulbecco's phosphate buffered saline (DPBS, Ca 2+-and Mg 2 § free) with 1 mM PMSF and 0.03% PEG was added to obtain a solution consisting of 100 mg wet sample per millilitre of buffer. After homogenization with a glass homogenizer, cytosols were obtained by ultracentrifugation (100000 x g for 1 h), then sterile filtered and stored at -70 ~ C.
Neutralization assay using anti-TGF~ l serum
Monoclonal antibody (40 gl, 150 ng/well) against TGF/~I (1D 11.16) was added to 96-well flat-bottomed tissue culture plates and preincubated with 40 gl TGF/~I (0.5 ng/well) or undiluted TSK G2000SW fraction pools containing IL-1 inhibitory activity for 2 h at 37~ Then 40 gl of each of the following were added to achieve the indicated concentrations: rIL-1/~ (1 U/well), PHA (2 gg/well), and LBRM.33 cells (105 cells/well). The cultures were then incubated for 24 h at 37~ The IL-1 inhibitor assay was then continued as described above.
Fast protein liquid chromatography (FPLC)
The biopsy cytosol (2 ml) was applied to a TSK G2000SW column equilibrated with DPBS plus 0.03% PEG. The flow rate was 1.0 ml/ min and 2.0 ml fractions were collected. The column was calibrated with bovine serum albumin (Sigma, 66000 MW), carbonic anhydrase (Sigma, 29000 MW), cytochrome C (Sigma 12400 MW) and aprotinin (Sigma, 6500 MW). Each fraction was sterilized with a 0.2 gm millipore filter and assayed for the presence of IL-1 inhibitory activity.
TSK G2000SW fractions with inhibitory activity were pooled, dialyzed against 0.025 M Bis-Tris (pH 6.3) and loaded into a Mono P column (0.5 x 20 cm) equilibrated with 0.025 M Bis-Tris (pH 6.3). The column was eluted with 10% polybuffer 74 (pH 4.0) at a rate of 0.5 ml/min and 1 ml fractions were collected. Fractions were dialyzed against DPBS using dialysis membrane with a 12000-14000 MW cut-off (Spectra, Por, Los Angeles, Calif., USA). Fractions were then sterile filtered and assayed for IL-1 inhibitory activity.
IL-1 inhibitory assay
Thymocyte proliferation. The presence of IL-1 inhibitory activity in biopsy cytosols was detected by inhibiting the co-proliferation signal of IL-1 upon mouse thymocytes stimulated with PHA. C3H/HeN mouse thymocyte cells (50 gl, 3 x 107/ml), 50 gl PHA (4 I, tg/ml), 50 gl rIL-1/~ (1.4 U/ml) and 50 gl biopsy cytosol at various dilutions were added per well of 96-well flat-bottomed plates. Each dilution and controls were done in triplicate. After a 3-day incubation period at 37~ thymocytes were pulsed with 1 gCi 3H-thymidine and incubated for another 6 h before harvesting and counting on a liquid scintillation counter.
LBRM.33 IL-2 production.
Alternatively, IL-1 inhibitory activity was measured by blocking the production of IL-2 by LBRM.33 cells in response to IL-1. Fractions from the TSK G2000SW column were tested for IL-1 inhibitory activity. Each undiluted fraction (50 gl) was added to LBRM.33 cells (50 gl, 105 cells/well), PHA (50 gl, 10 gg/well) and rIL-1/~ (50 gl, 1 U/well) in flat-bottomed 96-well microtiter tissue culture plates and the mixture incubated for 24 h at 37~ Supernatants from stimulated LBRM.33 cells were serially diluted, and 100 gl of each dilution was then transferred
Cell proliferation inhibition assays
A squamous cell carcinoma cell line (SCC 38) (100 gl) provided by Dr. T. E. Carey (Department of Otorhinolaryngology, University of Michigan Medical School) [22] or low passage human dermal fibroblasts (105 cells/ml) were added to each well of flat-bottomed 96-well tissue culture plates and incubated overnight at 37 ~ C. Medium was removed and 50 gl fresh medium and 50 Ixl undiluted fractions or DPBS were added to each well. Cells were then incubated for 48 h, pulsed with 1 gCi 3H-thymidine per well for 6 h, harvested using a PHD cell harvester and counted in the presence of Bio-Safe liquid scintillation fluid.
HT-2 cellular proliferation was measured by the degree of MTT reduced. HT-2 cells (20 [xl, 5 x 10S/ml) were added to 50 gl 5% Rat TCGF and 50 gl undiluted fractions. After a 48 h incubation period at 37~ 10 IA MTT (5 mg/ml) was added and incubated for another 4 h at 37~ The OD of reduced MTT was measured by an ELISA reader using wavelengths of 570 and 670 nm as described by Mosmann [35] . The amount of suppression of HT-2 growth was calculated by dividing the delta absorbance obtained in the presence of fractions by that obtained with cells grown without fractions but in the presence of 5% rat TCGF.
Results
Psoriatic cytosolic extracts of involved, but not uninvolved, skin block IL-1 activity in the thymocyte proliferation assay
The thymocyte co-stimulation assay assesses the costimulatory activity of IL-1 with suboptimal doses of PHA to activate murine thymocytes. When skin cytosols were added to murine thymocytes stimulated with PHA and a known amount of IL-1/~, psoriatic cytosols from involved skin, but not cytosols from uninvolved skin, blocked the IL- 
- Data is representative of six and three independent fractionations of psoriatic and normal keratome biopsy cytosols, respectively ( Fig. 1) . Cytosols from lesional psoriatic skin were virtually devoid of IL-1 activity in the mouse thymocyte assay (mean _+ SEM, 3900 _+ 1290 cpm; n = 11), whereas, uninvolved psoriatic skin (mean _+ SEM, 15 300 _+ 3522 cpm; n = 10) and control skin (mean _+ SEM, 20948 • 7030 cpm; n = 6) contained substantial activity, similar to our previous findings utilizing the LBRM.33 cell line [9] .
Detection of lL-1 inhibitory activity in size-fractionated psoriatic epidermal cytosols
To determine whether IL-1 inhibitory activity in psoriatic skin was similar in size to previously described IL-1 inhibitors, cytosols were size-fractionated by FPLC. The fractions were then tested for suppression of IL-I stimulation of LBRM.33 cells, an assay that is more specific for IL-1 than the thymocyte proliferation assay. Psoriatic keratome biopsy cytosols, when fractionated by FPLC on a TSK G2000SW column, revealed the presence of a molecule of about 30 kDa with IL-1 inhibitory activity (Fig. 2, solid line) . When normal keratome biopsy cytosol of equivalent protein concentration was fractionated in a similar manner, no IL-I inhibitory activity was observed at this molecular weight (Fig. 2, dashed line) .
Epidermal IL-1 inhibitor pI differs from EC-contra-IL-1
Because of the similarity in molecular weight with the UV-inducible epidermal-contra-IL-1 molecule, the isoelectric point of the psoriatic epidermal IL-1 inhibitor was determined. The 30 kDa fractions from the TSK G2000SW column with IL-1 inhibitory activity were pooled and chromatofocused by FPLC on a Mono P column. IL-I inhibitory activity eluted at pH 5.3 (Fig. 3) . This is much more acidic than the pI 8.8 reported for ECcontra-IL-1 [40] . 
Epidermal IL-1 inhibitor is not TGF~I
The homodimer form of TGF/?] (MW, 25 kDa) is a known inhibitor of IL-1 action [46] and is also similar in molecular weight to the epidermal IL-I inhibitor (MW, 30 kDa). We, therefore, determined whether the IL-1 inhibitory activity could be neutralized by a neutralizing anti-TGF/~l monoclonal antibody. TGF/~I was indeed capable of inhibiting the response of LBRM.33 cells to IL-1 (Fig. 4, second bar) . A monoclonal antibody against TGF/?I (1D1.116) was able to neutralize the TGF/~I inhibitory activity (Fig. 4, third bar) . However, when this monoclonal antibody was added to the epidermal IL-1 inhibitor no effect was observed on the IL-1 inhibitory activity (Fig. 4, fifth bar) . Even when the monoclonal antibody concentration was utilized at a concentration 100 times that used in Fig. 4 , no neutralization of the Ant~ TGF IL--1 TGF betal Ir'~lbltOr beta1 
Epidermal IL-1 inhibitor does not non-specifically inhibit cell growth
The 30 kDa epidermal IL-1 inhibitor was added to other cell types to determine if it affects the growth response of the HT-2 T-cell clone to IL-2 or has antiproliferative effects upon other cells such as a squamous carcinoma cell line (SCC38) or dermal fibroblasts (Fig. 6 ). When the epidermal IL-1 inhibitor was added directly to HT-2 cells stimulated with IL-2, no effect upon HT-2 proliferation was observed (Fig. 6) . No effect of the inhibitor was observed on proliferation of dermal fibroblasts or the SCC 38 cell line, as measured by 3H-thymidine uptake (Fig. 6) . By contrast, the same semi-purified 30 kDa inhibitor used in the above experiments completely suppressed the IL-I response of LBRM.33 cells (Fig. 6 ).
Epidermal IL-1 inhibitor has a delayed inhibitory effect
A recently cloned IL-1 receptor antagonist encodes for a protein of 17-25 kDa MW that inhibits IL-1 activity by competing for binding to the IL-1 receptor [5, 21] . If the psoriatic epidermal IL-1 inhibitor was acting by blocking the IL-1 receptor, then addition of the IL-1 inhibitor 4 h after exposure of the LBRM.33 cells to IL-1 should result in no inhibition. Binding of IL-1 molecules to IL-1 receptors expressed on LBRM.33 cells is rapid, with equilibrium being reached within 1 h [13] . When the 30 kDa IL-1 inhibitor was given to LBRM.33 cells 4 h after IL-1 stimulation, only one-third of the normal IL-1 response was observed (Fig. 5) . The degree of delayed inhibition of LBRM.33 IL-2 production by inhibitor ranged from
Discussion
We have demonstrated the presence of an epidermal IL-1 inhibitor in psoriatic lesions. The expression of this inhibitor, in concert with previously described reduced ILl c~ levels, accounts for the virtual absence of IL-1 activity in the intraepidermal compartment of psoriatic lesions. This IL-1 inhibitor has a molecular weight of approximately 30 kDa by FPLC on a silica gel column and a pI of 5.3. It also specifically inhibits IL-l-stimulated responses without affecting fibroblast or squamous cell carcinoma cellular growth or the response of a T-cell line, HT-2, to IL-2. These properties would suggest that it is not like other known epidermal inhibitors of IL-l-inducible responses.
TGFfll is produced by keratinocytes [15] and is capable of inhibiting the response of T cells to IL-I [46] . Thus, the 30 kDa epidermal IL-1 inhibitory activity could be attributed to the TGFfll produced by keratinocytes. Three lines of evidence suggest that this molecule is not TGFfll. First, the IL-1 inhibitory molecule did not alter fibroblast proliferation, either by stimulating or inhibiting growth, known properties of TGFfll [43] . Much stronger evidence is provided by the inability of a neutralizing monoclonal antibody to TGF/~I to neutralize the 30 kDa epidermal IL-1 inhibitory activity. Finally, the pI of TGFfll, which ranges between 6.8 and 7.4 [39] , is distinct from that of the inhibitor detected in psoriasis.
The other known IL-1 inhibitor present in the epidermis is inducible by UVB radiation. This IL-1 inhibitor, also known as EC-contra-lL-1, has a molecular weight of 40 kDa and a pI of 8.8 [40] . The smaller size of the IL-1 inhibitor described in this study, its much more acidic pI and its lack of induction in keratinocytes by UVB (data not shown) appear to distinguish it from ECcontra-IL-1.
The size (17-25 kDa) and pI (4.5-5.3) ranges of the IL-1 receptor antagonist produced by peripheral blood mononuclear cells are similar to the physicochemical characteristics of the inhibitor detected in psoriatic cytosols, albeit somewhat smaller in size [24, 42] . The ability of the epidermal IL-l inhibitor activity to act 4 h after IL-1 stimulation would suggest that the epidermal protein's activity is not limited to IL-1 receptor antagonism [5, 2l] . It has recently been demonstrated that a natural IL-1 inhibitor which acts as a receptor antagonist has to be added within 20 min of IL-1 in order to be effective [33] . This question will finally be clarified by the determination of the amino-acid sequence of the epidermal IL-1 inhibitor contained in psoriatic epidermis; however, we have not yet been able to obtain amino-acid analysis of our epidermal material due to insufficient purity.
Other potentially related inhibitory activities produced by the epidermis might include products of arachidonic acid metabolism [4, 45] , chalone-like growth inhibitors [6, 7, 32] , growth-inhibitory pentapeptides [16] and proteins [23] . The small size of these molecules and their generalized effects on cell lines and bioassays tends to make them unlikely candidates.
Our failure to detect the epidermal IL-I inhibitor in normal epidermis could be due to either the restriction of expression of the molecule to psoriatic lesions or the high levels of IL-le in normal epidermis compared with psoriatic lesions. Psoriatic fractions from the TSK G2000SW column containing IL-1 inhibitory activity also lacked significant levels of IL-lcc However, equivalent fractions in the region where IL-1 inhibitory activity is observed in psoriatic extracts from fractionated normal keratome biopsy cytosol possessed high levels of IL-lc~ (not shown), suggesting that the lack of IL-1 inhibitory activity in the normal fractions may be due to the presence of endogenous IL-1 e molecules which overwhelm the ILl inhibitory activity. However, the cellular source of this IL-1 inhibitor is not clear due to the large number of inflammatory cells present in psoriatic lesions, such as monocytes, that could be producing IL-I inhibitors [21] . This may explain the presence of this IL-1 inhibitor in psoriatic skin and its apparent absence in normal epidermis.
The occurrence of constitutively produced IL-I~ and fl molecules in the epidermis would predict the presence of a balancing IL-1 inhibitor which could specifically regulate IL-I responses in the skin. Such an IL-1 inhibitor may be needed where the release of large amounts of IL-1 by the keratinocytes would affect a wide variety of cells such as fibroblasts, endothelial cells, Langerhans cells, T cells and even keratinocytes [12] . Because IL-I drives activated T cells to differentiate toward a TH2 phenotype (high IL-4, low 7-interferon), low IL-1 activity due to the combination of an IL-1 inhibitor and low IL-I~ [9, 44] might explain the tendency of psoriatic skin to harbor CsA-sensitive T cells that produce ?-interferon [1, 2, 8, 19, 20, 34] , that is a TH~ phenotype [36] , and to Koebnerize with 7-interferon [17, 25] . Because of the diversity of cells affected by epidermal IL-1 molecules, an IL-I inhibitor that would specifically modulate the IL-1 response and not affect other cellular functions might play a critical role. The IL-I inhibitor isolated from psoriatic epidermis, and possibly normal epidermis, could thus be involved in the down-regulation of IL-l-mediated responses in psoriatic skin [10] .
